Company profile ATNM

Actinium Pharmaceuticals Inc
actinium pharmaceuticals, inc. (www.actiniumpharma.com) (nyse mkt: atnm) is a new york-based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. actinium's targeted radiotherapy is based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting actinium-225 and bismuth-213 and ce...rtain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. the company’s lead radiopharmaceutical iomab™-b will be used in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. the company is preparing a single, pivotal, multicenter phase 3 clinical study of iomab™-b in refractory and relapsed acute myeloid leukemia (aml) patients over the age of 55 with a primary endpoint of durable complete remission. the company’s second program, actimab-a, is continuing its clinical development in a phase 1/2 trial for newly diagnosed aml patients o Show More
Quarter analysis & expected interestLast update: February 08 2024 15:35:16.

After 39 days of this quarter the interest is at 17.0. Based on that we can calculate that during remaining 52 days it will total up to 40.0.
Actinium Pharmaceuticals expected interest is significantly lower compared to same quarter last year (-73.5%) but similar to previous quarter.

YearQ1Q2Q3Q4
201993
100
7.5% QoQ
76
-24.0% QoQ
91
19.7% QoQ
2020 125
34.4% YoY 37.4% QoQ
368
268.0% YoY 194.4% QoQ
519
582.9% YoY 41.0% QoQ
126
38.5% YoY -75.7% QoQ
2021 64
-48.8% YoY -49.2% QoQ
109
-70.4% YoY 70.3% QoQ
49
-90.6% YoY -55.0% QoQ
73
-42.1% YoY 49.0% QoQ
2022 41
-35.9% YoY -43.8% QoQ
75
-31.2% YoY 82.9% QoQ
41
-16.3% YoY -45.3% QoQ
67
-8.2% YoY 63.4% QoQ
2023 151
268.3% YoY 125.4% QoQ
80
6.7% YoY -47.0% QoQ
116
182.9% YoY 45.0% QoQ
41
-38.8% YoY -64.7% QoQ
2024 17
-88.7% YoY -58.5% QoQ
- - -
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and Actinium Pharmaceuticals search interestLast update: February 08 2024 15:35:16.
Correlation coefficient between keyword and revenue is -0.39
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: February 08 2024 15:35:17.

The average 5 years interest of Actinium Pharmaceuticals was 9.28 per week.
The last year interest of Actinium Pharmaceuticals compared to the last 5 years has changed by -29.74%.
This is something to be checked.
The last year interest is quite lower compared to 5 years ago. It has decreased by -18.7%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Actinium Pharmaceuticals cancer treatment to provide analysis

Correlation between past revenue and Actinium Pharmaceuticals cancer treatment search interest

There is not enough data for Actinium Pharmaceuticals cancer treatment to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Actinium Pharmaceuticals cancer treatment to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Actinium Pharmaceuticals Iomab-B to provide analysis

Correlation between past revenue and Actinium Pharmaceuticals Iomab-B search interest

There is not enough data for Actinium Pharmaceuticals Iomab-B to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Actinium Pharmaceuticals Iomab-B to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Actinium Pharmaceuticals targeted radiotherapies to provide analysis

Correlation between past revenue and Actinium Pharmaceuticals targeted radiotherapies search interest

There is not enough data for Actinium Pharmaceuticals targeted radiotherapies to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Actinium Pharmaceuticals targeted radiotherapies to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Actinium Pharmaceuticals clinical trials to provide analysis

Correlation between past revenue and Actinium Pharmaceuticals clinical trials search interest

There is not enough data for Actinium Pharmaceuticals clinical trials to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Actinium Pharmaceuticals clinical trials to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interestLast update: February 08 2024 15:35:22.

After 39 days of this quarter the interest is at 20.0. Based on that we can calculate that during remaining 52 days it will total up to 47.0.
That appears to be equal to previous quarter and same quarter last year.

YearQ1Q2Q3Q4
201973
126
72.6% QoQ
99
-21.4% QoQ
69
-30.3% QoQ
2020 118
61.6% YoY 71.0% QoQ
326
158.7% YoY 176.3% QoQ
539
444.4% YoY 65.3% QoQ
137
98.6% YoY -74.6% QoQ
2021 72
-39.0% YoY -47.4% QoQ
87
-73.3% YoY 20.8% QoQ
34
-93.7% YoY -60.9% QoQ
119
-13.1% YoY 250.0% QoQ
2022 17
-76.4% YoY -85.7% QoQ
41
-52.9% YoY 141.2% QoQ
38
11.8% YoY -7.3% QoQ
106
-10.9% YoY 178.9% QoQ
2023 78
358.8% YoY -26.4% QoQ
18
-56.1% YoY -76.9% QoQ
65
71.1% YoY 261.1% QoQ
51
-51.9% YoY -21.5% QoQ
2024 20
-74.4% YoY -60.8% QoQ
- - -
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and Actinium Pharmaceuticals stock search interestLast update: February 08 2024 15:35:21.
Correlation coefficient between keyword and revenue is -0.33
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: February 08 2024 15:35:23.

The average 5 years interest of Actinium Pharmaceuticals stock was 8.56 per week.
The last year interest of Actinium Pharmaceuticals stock compared to the last 5 years has changed by -57.13%.
This is something to be checked.
The last year interest is quite lower compared to 5 years ago. It has decreased by -53.25%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interestLast update: February 08 2024 15:35:29.

After 39 days of this quarter the interest is at 12.0. Based on that we can calculate that during remaining 52 days it will total up to 28.0.
Actinium Pharmaceuticals -stock -company expected interest is significantly lower compared to previous quarter (-67.1%) and same quarter last year (-84.7%).

YearQ1Q2Q3Q4
2019123
146
18.7% QoQ
100
-31.5% QoQ
227
127.0% QoQ
2020 199
61.8% YoY -12.3% QoQ
410
180.8% YoY 106.0% QoQ
540
440.0% YoY 31.7% QoQ
140
-38.3% YoY -74.1% QoQ
2021 19
-90.5% YoY -86.4% QoQ
174
-57.6% YoY 815.8% QoQ
69
-87.2% YoY -60.3% QoQ
70
-50.0% YoY 1.4% QoQ
2022 109
473.7% YoY 55.7% QoQ
113
-35.1% YoY 3.7% QoQ
101
46.4% YoY -10.6% QoQ
90
28.6% YoY -10.9% QoQ
2023 183
67.9% YoY 103.3% QoQ
160
41.6% YoY -12.6% QoQ
143
41.6% YoY -10.6% QoQ
85
-5.6% YoY -40.6% QoQ
2024 12
-93.4% YoY -85.9% QoQ
- - -
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and Actinium Pharmaceuticals -stock -company search interestLast update: February 08 2024 15:35:29.
Correlation coefficient between keyword and revenue is -0.33
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: February 08 2024 15:35:30.

The average 5 years interest of Actinium Pharmaceuticals -stock -company was 12.31 per week.
The last year interest of Actinium Pharmaceuticals -stock -company compared to the last 5 years has changed by -19.42%.
This is something to be checked.
The last year interest is quite lower compared to 5 years ago. It has decreased by -23.46%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Actinium Pharmaceuticals reviews to provide analysis

Correlation between past revenue and Actinium Pharmaceuticals reviews search interest

There is not enough data for Actinium Pharmaceuticals reviews to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Actinium Pharmaceuticals reviews to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Actinium Pharmaceuticals CAR T-cell therapy to provide analysis

Correlation between past revenue and Actinium Pharmaceuticals CAR T-cell therapy search interest

There is not enough data for Actinium Pharmaceuticals CAR T-cell therapy to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Actinium Pharmaceuticals CAR T-cell therapy to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Actinium Pharmaceuticals CD33 to provide analysis

Correlation between past revenue and Actinium Pharmaceuticals CD33 search interest

There is not enough data for Actinium Pharmaceuticals CD33 to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Actinium Pharmaceuticals CD33 to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Useful links and data for ATNM
Earnings date: 2024-03-31 After close
Company name: Actinium Pharmaceuticals Inc
Sector: Manufacturing
Company's website
Hypercharts
Yahoo Finance
MarketWatch
StockTwits
SEC Filings
SwaggyStocks
Latest articles

2026-05-06T08:00:00-04:00

PR Newswire
Actinium Pharmaceuticals Announces Three SNMMI 2026 Presentations Highlighting Differentiated Profile of ATNM-400 Across Lung and Prostate Cancer and Radioconjugate Optimization

2026-04-22T07:00:00-04:00

PR Newswire
Actinium Pharmaceuticals, Inc. Announces Compelling Pan-Tumor Data for ATNM-400 Demonstrating Broad Efficacy Across Prostate, Lung, and Breast Cancer Models at the 2026 American Association of Cancer Research Annual Meeting

2026-04-22T07:00:00-04:00

PR Newswire
Actinium Highlights Transcriptional Reprogramming as a Key Mechanism Underpinning Mutation-Agnostic Activity of Actimab-A in AML at the 2026 American Association of Cancer Research Annual Meeting

2026-04-06T07:30:00-04:00

PR Newswire
Actinium Pharmaceuticals Announces New Pan-Tumor Preclinical Data for ATNM-400 in Solid Tumors and Differentiated Mechanism for Actimab-A in AML to be Presented at 2026 AACR Annual Meeting

2026-03-31T13:08:28Z

Analyst Upgrades
Stephens & Co. Reiterates Overweight on Actinium Pharma, Maintains $5 Price Target

2026-02-17T07:42:00-05:00

PR Newswire
Actinium Pharmaceuticals, Inc. to Present Two Abstracts at the 2026 AACR Annual Meeting

2025-12-12T08:45:00-05:00

PR Newswire
Actinium Pharmaceuticals Presents New Preclinical Data Demonstrating Potent Anti-Tumor Activity of ATNM-400 Across Multiple Breast Cancer Subtypes Including Hormone Receptor-Positive, Triple-Negative, and Tamoxifen- and HER2 Therapy-Resistant Breast Cancer Models at SABCS 2025

2025-12-01T08:45:00-05:00

PR Newswire
Actinium Pharmaceuticals Announces ATNM-400 Data Demonstrating Potent Efficacy in Triple-Negative Breast Cancer and Ability to Overcome Endocrine and HER2-Targeted Therapy Resistance Being Presented at the San Antonio Breast Cancer Symposium

2025-11-04T07:30:00-05:00

PR Newswire
Actinium Pharmaceuticals, Inc. to Highlight ATNM-400 Data in Hormone-Resistant and HER2-Resistant Breast Cancer at the 2025 San Antonio Breast Cancer Symposium, Expanding Pan-Tumor Profile Across Three Solid Tumor Indications

2025-11-03T08:30:00-05:00

PR Newswire
Actinium Pharmaceuticals, Inc. to Participate in the Stephens Biotechnology Virtual Fireside Chat Conference

2025-10-27T07:00:00-04:00

PR Newswire
Actinium Announces Superior Anti-Tumor Activity of ATNM-400 in Lung Cancer Compared to the Leading First, Second and Third-Line Approved EGFR Mutant Therapies and Mechanistic Synergy with Osimertinib at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

2025-10-24T08:30:00-04:00

PR Newswire
Actinium Pharmaceuticals Presents New Data Demonstrating Potent and Durable Efficacy of ATNM-400, a First-in-Class Multi-Tumor Actinium-225 Radiotherapy, at the 32nd Annual Prostate Cancer Foundation Scientific Retreat

2025-10-13T12:10:00-04:00

PR Newswire
Actinium Pharmaceuticals to Unveil the Multi-Tumor Potential of ATNM-400, a First-in-Class Actinium-225 Radiotherapy, with Data in Non-Small Cell Lung Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

2025-10-13T08:30:00-04:00

PR Newswire
Actinium to Present ATNM-400 Preclinical Data Highlighting Durable Tumor Control and Ability to Overcome Resistance to Standard-of-Care Prostate Cancer Therapies at the 32nd Annual Prostate Cancer Foundation Scientific Retreat

2025-08-08T17:00:44-04:00

SEC
10-Q Form - Quarterly report [Sections 13 or 15(d)] - Actinium Pharmaceuticals, Inc. (0001388320) (Filer)